GGHC
DNLI icon

Gilder Gagnon Howe & Co’s Denali Therapeutics DNLI Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,172,785
Closed -$24.1M – 259
2024
Q1 		$24.1M Sell
1,172,785
-46,607
-4% -$876K 0.3% 76
2023
Q4 		$26.2M Sell
1,219,392
-26,807
-2% -$531K 0.36% 68
2023
Q3 		$25.7M Sell
1,246,199
-333,746
-21% -$8.47M 0.39% 61
2023
Q2 		$46.6M Sell
1,579,945
-76,452
-5% -$2.15M 0.64% 44
2023
Q1 		$38.2M Sell
1,656,397
-110,745
-6% -$3.05M 0.63% 45
2022
Q4 		$49.1M Sell
1,767,142
-96,135
-5% -$2.86M 0.92% 35
2022
Q3 		$57.2M Sell
1,863,277
-93,543
-5% -$3.04M 1% 24
2022
Q2 		$57.6M Sell
1,956,820
-662,397
-25% -$17.4M 1.03% 24
2022
Q1 		$84.3M Sell
2,619,217
-280,897
-10% -$9.67M 0.78% 41
2021
Q4 		$129M Buy
2,900,114
+97,120
+3% +$4.6M 0.74% 42
2021
Q3 		$141M Sell
2,802,994
-32,739
-1% -$1.85M 0.73% 41
2021
Q2 		$222M Sell
2,835,733
-168,820
-6% -$10.4M 1.09% 23
2021
Q1 		$172M Sell
3,004,553
-215,290
-7% -$14.4M 0.92% 30
2020
Q4 		$270M Sell
3,219,843
-96,287
-3% -$5.82M 1.34% 17
2020
Q3 		$119M Sell
3,316,130
-69,103
-2% -$2.08M 0.73% 39
2020
Q2 		$81.9M Buy
3,385,233
+124,211
+4% +$2.92M 0.64% 52
2020
Q1 		$57.1M Buy
+3,261,022
New +$68M 0.68% 55
2019
Q2 		– Sell
-596
Closed -$14K – 290
2019
Q1 		$14K Sell
596
-191
-24% -$4K ﹤0.01% 275
2018
Q4 		$16K Sell
787
-12,021
-94% -$218K ﹤0.01% 265
2018
Q3 		$278K Sell
12,808
-808
-6% -$13.4K ﹤0.01% 254
2018
Q2 		$208K Sell
13,616
-67
-0.5% -$1.26K ﹤0.01% 255
2018
Q1 		$269K Sell
13,683
-1,447
-10% -$29.7K ﹤0.01% 260
2017
Q4 		$237K Buy
+15,130
New +$272K ﹤0.01% 265

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Gilder Gagnon Howe & Co's DNLI Position: Q2 2024 in Review

Gilder Gagnon Howe & Co sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 1,172,785 shares — an estimated $24.1M sold.

Gilder Gagnon Howe & Co first reported a position in DNLI in Q4 2017 and held it in 23 quarters. The position peaked at $270M in Q4 2020. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

  • Gilder Gagnon Howe & Co reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 1,172,785 Denali Therapeutics shares in Q2 2024, an estimated $24.1M.
  • Gilder Gagnon Howe & Co first reported a position in Denali Therapeutics in Q4 2017 and held it in 23 quarters.
  • Gilder Gagnon Howe & Co's Denali Therapeutics position peaked at $270M in Q4 2020.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2024, filed 14 Aug 2024.